Special Infectious Agents Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.
Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia.
Vox Sang. 2021 Jul;116(6):673-681. doi: 10.1111/vox.13043. Epub 2020 Dec 5.
During the ongoing pandemic of COVID-19, SARS-CoV-2 RNA was detected in plasma and platelet products from asymptomatic blood donors, raising concerns about potential risk of transfusion transmission, also in the context of the current therapeutic approach utilizing plasma from convalescent donors. The objective of this study was to assess the efficacy of amotosalen/UVA light treatment to inactivate SARS-CoV-2 in human plasma to reduce the risk of potential transmission through blood transfusion.
Pools of three whole-blood-derived human plasma units (630-650 ml) were inoculated with a clinical SARS-CoV-2 isolate. Spiked units were treated with amotosalen/UVA light (INTERCEPT Blood System™) to inactivate SARS-CoV-2. Infectious titres and genomic viral load were assessed by plaque assay and real-time quantitative PCR. Inactivated samples were subject to three successive passages on permissive tissue culture to exclude the presence of replication-competent viral particles.
Inactivation of infectious viral particles in spiked plasma units below the limit of detection was achieved by amotosalen/UVA light treatment with a mean log reduction of >3·32 ± 0·2. Passaging of inactivated samples on permissive tissue showed no viral replication even after 9 days of incubation and three passages, confirming complete inactivation. The treatment also inhibited NAT detection by nucleic acid modification with a mean log reduction of 2·92 ± 0·87 PFU genomic equivalents.
Amotosalen/UVA light treatment of SARS-CoV-2 spiked human plasma units efficiently and completely inactivated >3·32 ± 0·2 log of SARS-CoV-2 infectivity, showing that such treatment could minimize the risk of transfusion-related SARS-CoV-2 transmission.
在当前 COVID-19 大流行期间,从无症状献血者的血浆和血小板产品中检测到了 SARS-CoV-2 RNA,这引发了人们对潜在输血传播风险的担忧,特别是在当前利用恢复期献血者血浆进行治疗的情况下。本研究的目的是评估亚甲蓝光化学法/紫外线(UVA)灭活 SARS-CoV-2 在人血浆中的效果,以降低通过输血传播的潜在风险。
将三个人全血来源的血浆单位(630-650ml)的混合液接种临床 SARS-CoV-2 分离株。用亚甲蓝光化学法/紫外线(INTERCEPT Blood System™)处理加标单位以灭活 SARS-CoV-2。通过噬斑法和实时定量 PCR 评估感染性滴度和基因组病毒载量。将灭活样本进行连续三次传代培养,以排除复制型病毒颗粒的存在。
亚甲蓝光化学法/紫外线处理可使加标血浆单位中的传染性病毒颗粒失活,达到检测下限以下,平均 log 减少 >3·32±0·2。在允许的组织培养物上对灭活样本进行传代培养,即使孵育 9 天和传代三次后,也未观察到病毒复制,从而确认完全失活。该处理还通过核酸修饰抑制了 NAT 检测,平均 log 减少 2·92±0·87 PFU 基因组当量。
亚甲蓝光化学法/紫外线处理 SARS-CoV-2 加标人血浆单位可有效且完全地灭活 >3·32±0·2 log 的 SARS-CoV-2 感染性,表明这种处理方法可最大限度地降低输血相关 SARS-CoV-2 传播的风险。